Bone: Arthritis and Osteoporosis

Tenofovir disoproxil fumerate (TDF), a nucleotide reverse transcriptase inhibitor associated with fracture risk, may be prescribed selectively to older versus younger women. Our objective is to examine the association of age and fracture risk with antiretroviral therapy (ART) use among women with Hu...

Full description

Saved in:
Bibliographic Details
Published in:Innovation in aging 2018-11, Vol.2 (suppl_1), p.302-302
Main Authors: Bozzi, L, Spence, O, Stafford, K, dosReis, S
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tenofovir disoproxil fumerate (TDF), a nucleotide reverse transcriptase inhibitor associated with fracture risk, may be prescribed selectively to older versus younger women. Our objective is to examine the association of age and fracture risk with antiretroviral therapy (ART) use among women with Human Immunodeficiency Virus (HIV+). Our study included 1,325 HIV+ non-pregnant women aged 30–60 enrolled in the Women’s Interagency HIV Study. We categorized age as younger (30–44 years) and older (45–60 years) women and ART as TDF-containing regimen, other ART, or no ART. Baseline fracture risk was defined by primary (race; body mass index; current smoking; alcohol use; previous fracture; parental fracture; rheumatoid arthritis/lupus) and secondary fracture risk factors (diabetes; hepatitis; intravenous drug use; low cd4 count). Multinomial logistic regression examined the association between age, baseline fracture risk, and ART, adjusting for demographic covariates (education; marital status; employment; income; years since HIV diagnosis). Of our sample, 37% were older women. Prevalence of TDF-containing regimens was greater in older versus younger women (56% vs 29%, p
ISSN:2399-5300
2399-5300
DOI:10.1093/geroni/igy023.1110